Wednesday, November 12, 2014 5:47:59 PM
looks like RXII is coming to a big inflection point/ crunch time , maybe tomorrow or the rest of this week, at this price zone 1.80-1.95 area is really a critical zone , I looked closely at all the price action over the last month or so, and its This area around 1.95, a balance point, 2 dollars, and 2.10 as a resistance wall..but 1.80 a critical support.
I appreciate the fundamental perspective because thats my own weakness /blindness. but a far as technical price action goes.... buyers were Very disappointed to see price Fail like it did around 2.10 area and when it fell below the key balance point around1.95 a week and a half ago, that was a momentum killer...now with momentum looking downward...its been equally critical to see price support Hold at 1.80,like it did today. Maybe theres alot of MM control here because it fell today on low volume, as if 20 thousand shares would cause a drastic plunge... is that normal? seems manipulated... but the key is, this 1.80 zone is being painted as critical support. and the 2.00 zone is resistance that needs to be broken through. Tomorrow, as price retests the key 1.95 zone, it wont be a good sign if price gets hit hard down from there. we really need to see some Buying step in now, and as was mentioned....volume has been low these days.... folks who jumped in at this price last week and previous few weeks at this entry price have been 3 times disappointed. If it happens again , and gets whacked down at 1.95-2.00....failing to break through 2 dollars.... this week, we could see a bigger selling effort try to retest the 1.60 zone all over again. 1.80 would likely get taken out.
I ,myself will plan to sell at this resistance wall if it cant break thru 1.95-2.00 this week.
(but thats not advice , just what my own plan is.)
I like the idea of the science and potential success....but the stock has taken a terrible collapse from the 3.40 zone and has taken this long to find its bottom. Maybe I'd buy it again at 1.60 later on. it does take time to form a Bottom.... the last bunch of small rallys have shown big resistance at lower highs , around 2.00/2.10/2.15-2.20 area...now the Bollinger top bands are around 2.25 area.... the technical picture for this chart is that it would be a great achivement just to get back to Big resistance at 2.50...and below that 2.25 is a big target zone. Theres not much profit for traders in this chart picture.
You either need to be a long term buy and holder who isnt concerned, or else not be in this one, as a trader.... its looking like a small fish to gain 25-35% profit here.
http://stockcharts.com/c-sc/sc?s=RXII&p=D&yr=0&mn=2&dy=2&i=p76326611415&r=1415832308052
and today was kind of strange too with the pop to 1.97 and the collapse to 1.80...
Its developed a triangle terminal here, and will make a move soon. Down is not what we want here.
This equity does not allow stop loss /sell orders....so I need to watch as soon as the market opens.
Any big reistance around 2.00 and I'm outta here.
Recent PHIO News
- Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO) • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells • GlobeNewswire Inc. • 04/22/2024 05:10:09 PM
- Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID) • GlobeNewswire Inc. • 04/16/2024 11:30:00 AM
- Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT) • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- National Spotlight Features Phio’s Innovative RNAi Technology Platform • GlobeNewswire Inc. • 04/03/2024 11:30:00 AM
- Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update • GlobeNewswire Inc. • 04/02/2024 11:30:00 AM
- Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies • GlobeNewswire Inc. • 03/21/2024 11:30:00 AM
- Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research • GlobeNewswire Inc. • 03/13/2024 06:00:25 PM
- Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders • GlobeNewswire Inc. • 03/06/2024 03:30:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 12:03:51 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:30:10 PM
- Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies • GlobeNewswire Inc. • 01/31/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 10:00:16 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/28/2023 02:13:20 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/28/2023 05:15:20 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/19/2023 09:52:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 10:00:32 PM
- Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:07 PM
- Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/09/2023 09:30:20 PM
- Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas • GlobeNewswire Inc. • 11/09/2023 12:30:00 PM
- Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control • GlobeNewswire Inc. • 11/03/2023 04:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM